Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2020-06-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad, MEDI4736 has on the
patient and cancer.
MEDI4736 is a type of medication called an antibody. Antibodies are normal proteins in the
body that help fight infections and possibly cancer. MEDI4736 is a special type of an
antibody produced in a laboratory. MEDI4736 works by blocking a specific protein called the
Programmed Death Ligand-1 (PDL-1), located on tumor cells.